Cabozantinib INN
Composition: Each film coated tablet contains Cabozantinib 60mg as Cabozantinib (S) Malate INN.
Indications:
Renal Cell Carcinoma: Cabozantinib is indicated for the treatment of
patients with advanced renal cell carcinoma (RCC). Hepatocellular Carcinoma:
Cabozantinib is indicated for the treatment of patients with hepatocellular
carcinoma (HCC) who have been previously treated with Sorafenib.
Dosage and Administration:
Recommended Dosage for Renal Cell Carcinoma: The recommended dosage of
Cabozantinib is 60mg once daily without food until the patient no longer
experiences clinical benefit or experiences unacceptable toxicity. Recommended
Dosage for Hepatocellular Carcinoma: The recommended dosage of Cabozantinib
is 60mg once daily without food until disease progression or unacceptable
toxicity. Or, as directed by the
registered physicians.
Use in Pregnancy and Lactation: Cabozantinib
can cause fetal harm when administered to a pregnant woman. There are no
available data in pregnant women to inform the drug-associated risk.
Packing: Each container contains 30 tablets in a box.